Join our newsletter
Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
Centrally acting Myorelaxant.
Indicated for spastic disorders associated with degenerative illnesses and cerebral palsy.
Excreted into breast milk in non-significant clinical amount with no harm effects reported among breastfed infants from treated mothers.
When administered in pregnancy, symptoms of Abstinence Syndrome may appear,
Intrathecal administration shows small serum levels by which it is assumed that the amount present in breast milk must be even lower.
Oral administration has been authorized since neonatal age in the UK and one year of life in Spain.
Follow-up of milk production is recommended since a theoretically based inhibition of Prolactin may occur.
American Academy of Pediatrics: medication usually compatible with breastfeeding.